New collaboration by GlaxoSmithKline and the University of Carolina to tackle HIV/Aids
British pharma giant GlaxoSmithKline is investing $4milion a year R&D into HIV/AIDS and will be teaming up with the University of Carolina Chapel Hill to create a HIV cure centre that will look solely at finding a cure for HIV/AIDS.
The University already has significant expertise and research into this problematic virus and is considered a centre of expertise.
The GSK Investment will be for five years, and a small research team from GSK will move to Chapel Hill to work with UNC researchers.
Plans will include a strategy known as ‘shock and kill’. This new method they hope will reveal the hidden virus that lingers in people with HIV infection despite successful drug therapy, and boost the patient’s immune system to clear the last traces of the virus and infected cells. The FDA has approved this new research.
GSK Chief Executive Sir Andrew Witty says - “Like UNC, GSK has a long legacy of HIV research success”
“From the development of the world’s first breakthrough medicine for HIV patients in the 1980s [Retrovir (azidothymidine) in 1987], to our leadership in the market today through ViiV Healthcare, we’re continuously challenging ourselves to meet the needs of patients.
“This partnership is a testament to our past and present leadership, innovation and commitment to this field. We are inspired by the confidence that with the right resources and research teams.